In recent years, the U.S. Food and Drug Administration has approved revised labeling for several existing drugs to include pharmacogenomic information, marking an important step toward more personalized medicine. In addition, it is anticipated that many newly approved drugs may be restricted to use in individuals with certain genotypes. In response to the wealth of pharmacogenetic data generated during the past decade and its implications for pharmacy practice, the American College of Clinical Pharmacy (ACCP) Educational Affairs Committee was charged with describing the basic science foundation necessary to prepare future pharmacists to manage personalized, pharmacogenetically driven therapy. The committee identified four key areas deemed essential components of the pharmacy curriculum related to advances in genomics: (1) personalized medicine concepts and terminology, with a focus on genomics;
Introduction
The American College of Clinical Pharmacy (ACCP) Educational Affairs Committee was charged with describing the basic science foundation necessary to prepare future pharmacists to manage personalized, pharmacogenetically driven therapy. As a precedent, one of the critical issues identified in ACCP's 2007-2012 Strategic Plan is, "How can ACCP increase its contribution to ensuring an appropriately educated and skilled clinical pharmacy workforce?" 1 The strategy for addressing this issue involves providing support for curricular content development and delivery in schools and colleges of pharmacy to better prepare the future clinical pharmacy workforce. The current committee charge is in response to the wealth of pharmacogenetic data generated during the past decade and the implications of these data on pharmacy practice. Substantial interpatient variability exists in drug response. Hence, it is difficult to predict an individual's risk of adverse effects or likelihood of therapeutic benefit with a prescribed drug.
Although clinical factors (e.g., age, comorbidities, concomitant therapy) are often considered when choosing drug therapy, these alone do not adequately predict drug response. It is now recognized that genetically determined differences in drug metabolism, drug distribution, disease-associated proteins, and drug target proteins play a major role in the observed interpatient variability in drug response. 2 In recent years, the U.S. Food and Drug Administration has approved revised labeling for several existing drugs (e.g., irinotecan, 6-mercaptopurine, warfarin, carbamazepine, phenytoin, abacavir, rasburicase) to include information on genetic variants linked to adverse drug effects or drug efficacy. 3 Clinicians are awaiting clinical trial data on the use of genotype-informed prescribing for some drugs (e.g., warfarin, clopidogrel) before adopting pharmacogenomics in routine clinical practice. 4, 5 Nonetheless, the addition of genetic 5 information to product labeling marks a considerable step toward more personalized medicine.
Similar to the prescribing recommendations for trastuzumab and cetuximab, several newly approved drugs may be restricted to use in individuals with certain genotypes. As experts in pharmacotherapy, pharmacists may well provide an increasingly valuable service in dealing with the complexities of the drug decision process in the era of personalized medicine.
Personalized medicine broadly refers to tailoring disease management on the basis of an individual's characteristics. In pharmacotherapy, personalized medicine involves basing drug therapy decisions on patient-specific factors such as clinical characteristics, genotype and gene expression, protein structure or function, and molecular profile. Pharmacogenomics, one component of personalized medicine, refers to the inherited basis for interindividual differences in drug response. The terms pharmacogenomics and pharmacogenetics are often used interchangeably. However, pharmacogenetics generally refers to a single gene influencing drug response, whereas pharmacogenomics refers to a combination of genes with effects on drug response. For simplicity, pharmacogenomics will be used to describe DNA sequence variation leading to alterations in drug response.
Proteomics, metabolomics, and epigenetics are other components of personalized medicine. Proteomics is the study of protein structure and function; metabolomics is the systemic analysis of biologic samples for small molecules (e.g., amino acids, carbohydrates, lipids, other organic compounds) generated by cellular processes. 6 Protein function and molecular composition are dynamic and may change upon drug exposure. This is in contrast to an individual's DNA sequence, which remains consistent throughout life and may lead to predictable changes in pharmacokinetic and/or pharmacodynamic drug properties. Epigenetics refers to changes in gene function or expression that occur in the absence of DNA sequence 6 alterations because of mechanisms such as DNA methylation, histone modification, or the expression of regulatory noncoding RNAs. 7 Pharmacy educators, practitioners, and regulators recognize the importance of addressing advances in personalized medicine and biotechnology in the pharmacy curricula. 8, 9 In particular, the Accreditation Council for Pharmacy Education (ACPE) identified the following elements as essential to the science foundation for the pharmacy curriculum in the 2007 ACPE Accreditation Standards and Guidelines. 10 • "Genetic basis for disease and drug action Professional Education in Genetics have provided guidance on particular curricular content deemed essential with respect to personalized medicine. 9, 11, 12 Both organizations suggest core competencies to be achieved, focusing on the genomic component of personalized medicine, but neither provides suggestions for specific curricular changes to address these competencies.
In this commentary, we propose basic science curricular content essential for preparing doctor of pharmacy graduates entering practice to appropriately manage pharmacotherapy in the era of personalized medicine. The content described is aimed at providing basic education for all pharmacy students, recognizing that some graduates will have a larger role in personalized medicine, perhaps from a research, regulatory, or technology perspective, and will require further 7 education and training postgraduation. The application of metabolomics to predicting drug response is largely in its infancy and thus is not addressed to a large extent in this commentary.
In addition, because protein function is largely under genetic control, this commentary will focus predominantly on genomic concepts. We wish to emphasize that personalized medicine also encompasses clinical factors, and clinicians should continue to consider these factors in drug therapy decisions. Hence, the content we recommend is meant to be integrated with existing curricula covering clinical variables that influence drug response. This commentary addresses four topics: personalized medicine concepts and terminology, with a focus on genomics;
genomic applications in basic and applied pharmaceutical sciences; biotechnology; and bioinformatics. Each section contains one or more broad curricular outcomes to be achieved, suggested implementations to address each outcome, and benchmark performance indicators of learning outcomes for recent graduates from doctor of pharmacy educational programs. Although valuable, the ethical, social, legal, and economic ramifications of pharmacogenomic testing are believed to be beyond the scope of the basic science curricular content necessary to prepare graduates to manage personalized medicine; thus, they are not discussed.
Personalized Medicine Concepts and Terminology
• Curricular Outcome #1: Describe the structure of the human genome and alterations in the genome that can affect gene function and expression.
• Curricular Outcome #2: Describe the relevance of DNA sequence variants and alterations in gene function and expression to drug response.
Discussion 8
Genetics revolutionized the biologic sciences, launched molecular biology, and formed the basis of pharmacogenomics and epigenetics. As pharmacogenomics continues to progress from a basic to a clinical science, it will affect patient care on many levels. To optimize pharmacotherapeutic outcomes, pharmacists will need a broad understanding of human genetics and the potential consequences of gene modification on disease phenotype and drug response. To appropriately interpret pharmacogenomic data, pharmacists should have a strong foundation in molecular biology and biochemistry that is focused on the structure and function of DNA and RNA, chromosome packaging, the processes of gene transcription and translation, and the structure and expression of human genes. In addition to prerequisite or early preprofessional coursework in human genetics, students should receive specific instruction and training on genetic variations and the associated implications for protein function during their professional years of pharmacy school. Such material may be integrated into an existing curriculum or taught in courses specifically focused on pharmacogenomics and epigenetics. 10 
Benchmark Performance Measures
• Pharmacy graduates will be able to describe various types of human genetic variation and genetic modifications leading to alterations in gene function and expression.
• Pharmacy graduates will be able to accurately predict the consequences of DNA sequence variation and epigenetic mechanisms on gene function, gene expression, protein structure, and protein function.
Genomic Applications in Basic and Applied Pharmaceutical Sciences
• Curricular Outcome #3: Describe the effects of DNA sequence variation and epigenetic mechanisms on human physiology.
• Curricular Outcome #4: Demonstrate proficiency in identifying genes and genetic variants with potential effects on drug response.
• Curricular Outcome #5: Predict the effects of variation in gene structure and expression on pharmacokinetics and pharmacodynamics.
• Curricular Outcome #6: Appropriately evaluate primary literature describing genetic association with drug therapy to assess its validity, limitations, and clinical significance.
• Curricular Outcome #7: Recognize and use online resources as sources of genetic information.
Discussion
The importance of genetic variation has expanded from its diagnostic value for inherited diseases to a tool for predicting physiologic differences and drug response. In addition to a fundamental knowledge of normal anatomy and physiology, an understanding of the genetic 11 influences of physiologic processes is essential for drug selection, dosing, use, and monitoring.
Diuretic therapy may be especially effective for an individual with hypertension and a genotype predictive of excessive sodium reabsorption. 13 However, amiodarone should be used with particular caution in patients with cardiac ion channel mutations that increase the risk of proarrhythmia. 14 Thus, to appropriately apply genetic information to pharmacotherapy decisions, graduates must understand the relationship between genotype and phenotype.
Genetic variability can also affect drug pharmacokinetics and pharmacodynamics. In particular, genetic variation with an impact on drug-metabolizing enzymes, drug transporter proteins, and proteins at the drug target level can have profound effects on drug disposition and sensitivity, thereby influencing the likelihood of drug efficacy or risk of adverse effects. 2 To be effective members of a multidisciplinary group charged with incorporating genetic information into clinical practice, pharmacists must understand the effects of genetic variation on disease phenotype, pharmacokinetics, and pharmacodynamics. Graduates should also be knowledgeable about labeling recommendations and requirements regarding pharmacogenomic dosing, and they should have the ability to effectively interpret and appropriately apply such recommendations.
Finally, basic skills in navigating and retrieving data from genetic databases will be valuable for fully characterizing drug effects on the basis of genetic information.
Suggested Implementation
Anatomy and physiology courses that are part of either the preprofessional or the early It is essential that pharmacy graduates be familiar with how to locate, navigate, and use Web sites, such as those previously listed, as resources of genomic information.
Benchmark Performance Measures
• Pharmacy graduates will be able to predict the effects of DNA sequence variation and epigenetic mechanisms on human physiology, pharmacokinetics, and pharmacodynamics.
• Pharmacy graduates will be proficient in the retrieval of genomic information from primary literature, genomic databases, and other resources to assist with drug therapy decisions. 14 • Pharmacy graduates will be able to appropriately assess the strengths, limitations, and clinical significance of genetic association studies.
• Pharmacy graduates will be able to apply concepts of genetic variability to individualize patient care plans and achieve optimal pharmacotherapeutic outcomes.
Biotechnology
• Curricular Outcome #8: Describe the basic utility and limitations of commonly used genetic assays.
• Curricular Outcome #9: Develop a basic understanding of interpretation of pharmacogenomic test results.
Discussion
The With the increased availability of genetic technology, including tests marketed directly to the consumer, patients may gain access to their genetic information with minimal counseling support. Pharmacists may assist patients with questions regarding test results, but theoretical comprehension of the science and technology alone will not provide a professional service to 15 patients. Therefore, it is recommended that pharmacists develop the skills necessary to interpret the following genetic information: genetic laboratory test results, assay accuracy and reliability, and limitations of methods and analyses.
As genetic medicine evolves, the pharmacy curricula will need to be flexible to adapt to the changing technology. In the future, scientists may find it necessary to sort through large amounts of genomic data to identify relevant information for pharmacotherapeutic decisionmaking. Although pharmacists will likely not be directly involved in interpreting complex genetic data, graduates should possess sufficient knowledge to allow effective communication with biostatisticians, bioinformatics specialists, and other genetic experts and be an integral part of an interdisciplinary group to optimize pharmacotherapy. This comprehension will be similar to the counseling competencies currently required for drugs and other pharmaceutical products, such as interpreting the INR in relation to warfarin therapy. Thus, pharmacy graduates, in collaboration with essential personnel, should be able to effectively interpret and apply laboratory findings to drug therapy.
Suggested Implementation
Whether obtained in the pharmacy curriculum or through prerequisite requirements, formal education in the classroom and/or laboratory is recommended. Student exposure should include access to current and accurate information provided by active genetic researchers in person or through alternative media formats. Pharmacy students should undergo training for interpreting pharmacogenetic testing results. The expertise of genetic researchers, biostatisticians, and others will be necessary to ensure that appropriate information is transferred. 16 Benchmark Performance Measures • Pharmacy graduates will be able to describe basic genotyping technology and its application to patient care.
• Pharmacy graduates will be able to effectively communicate with scientific experts and other clinicians for interpreting and addressing genetic test results with respect to pharmacotherapy.
• Pharmacy graduates will be able to effectively communicate with patients to explain pharmacogenetic test results and recognize when patient referral to an expert in genetics is necessary.
Bioinformatics
• Curricular Outcome #10: Show proficiency in the evaluation of genetic data and information.
Discussion
As genetic information is incorporated into therapeutic decision-making, the ability to manage and decipher large quantities of information will become increasingly valuable for health care professionals. Many genes and genetic variants likely influence the response to most drugs.
The ability to implement genetically guided therapeutic interventions will therefore require that data on several genes and gene variants be obtained, processed, analyzed, and interpreted appropriately and efficiently. This will likely require interdisciplinary efforts by scientists and clinicians. 17 Computational applications will be essential to decipher the large amount of data for a given patient that may be generated from sequencing and gene expression studies.
Bioinformatics is the use of computer programs or mathematic models to obtain useful information from "noisy" data that are caused by high-throughput assays, such as DNA sequencing and microarrays. The pharmacist will likely not need to be an expert in mathematic and statistical methodology in relation to pharmacogenomics. However, pharmacists should be familiar with genetic-based software programs, as they become available, and be able to assess output from probabilistic or other relevant models. more time devoted to genetically guided drug therapy. The application of genetically guided therapy could then be reinforced in a coordinated manner with a clinical pharmacotherapy course using available software programs or algorithms to predict drug response.
Benchmark Performance Measures
• Pharmacy graduates will show the ability to assess the strengths and limitations of the genetic algorithms and probabilistic models used to estimate appropriate drug therapy and/or dose.
• Pharmacy graduates will be able to use genomic-based software within the context of the patient's clinical factors to individualize therapy.
Summary
Ensuring that the pharmacy curriculum addresses issues with respect to advances in genomics is crucial for preparing the pharmacy workforce to perform valuable services in managing personalized, pharmacogenomically driven therapy. Our committee identified four key areas deemed essential components of the pharmacy curriculum: Although there were some differences in opinion among committee members with respect to the depth or extent of material taught in each of these sections, there was unanimous agreement that the curricular outcomes described were the minimum expectations for future pharmacists to provide optimal patient care in the era of personalized medicine. Schools may wish to offer elective courses to provide additional and more in-depth instruction in one or more subjects.
Material taught in each area should evolve together with progress in the field. This is particularly true for gene-drug response associations, biotechnology, and bioinformatics. Self-directed learning behavior should be encouraged whenever possible to better prepare students to advance their skills and knowledge of the science. Finally, faculty development will likely be necessary for the widespread education of pharmacy students in personalized medicine. Professional pharmacy organizations can provide a valuable service by providing this education.
